Predictive and Prognostic Significance of the State of Gene TOP2A as a Marker of Anthracyclines Sensitivity in Patients with Breast Cancer-Reference-Cited by-同舟云学术

Predictive and Prognostic Significance of the State of Gene TOP2A as a Marker of Anthracyclines Sensitivity in Patients with Breast Cancer

Published:2021-04-19 Issue:1 Volume: Page:64-73
ISSN:2309-7485
Container-title:Евразийский онкологический журнал
language:ru
Short-container-title:

Author:

Бармотько М.А.

Abstract

Представлен обзор литературы, посвященный изучению значимости состояния гена ТОР2А как фактора прогноза исхода заболевания и эффективности лечения антрациклинами у пациентов с раком молочной железы.A literature review was presented and devoted to study of significance gene TOP2A state as a factor in predicting the outcome of the disease and the efficacy of anthracyclines treatment in patients with breast cancer.

Publisher

Professionals Publications

Reference31 articles.

1. Okeanov A.E., Moiseev P.I., Levin L.F., Evmenenko A.A., Ipatij T.B. (2019) Rak v Belarusi: cifry i fakty. Analiz dannyh belorusskogo kancer-registra za2009–2018 gg. [Cancer in Belarus: facts and figures. Analysis of the data of the Belarusian Cancer Register for 2009-2018]. Minsk: Nacional'naya biblioteka Belarusi, 422 p.

2. Järvinen T.A. (1998) Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. Br. J. Cancer, vol. 77, no 12, pp. 2267–2273.

3. Di Leo A. (2002) HER-2 amplification and topoisomerase II gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin. Cancer Res, vol. 8, no 5, pp. 1107–1116.

4. Coon J.S. (2002) Amplification and overexpressionof topoisomerase II alpha predict response to anthracycline-based therapyin locally advanced breast cancer. Clin. Cancer Res, vol. 8, no 4, pp. 1061–1067.

5. Park K. (2002) Interaction between HER-2/neu and topoisomerase IIα amplification in preoperative doxorubicin-based chemotherapyfor locally advanced breast cancer: integration of novel chromogenic insitu hybridization and tissue microarray technology. Eur. J. Cancer, vol. 38, suppl. 3. S52.